SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as members of the community speculate on potential price recovery and future utility, while many users continue to share optimistic long-term sentiment regarding the project's growth. Discussions are largely fueled by traders looking for a breakout and long-term supporters expressing patience for the token to eventually gain broader market traction.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors react to its AI-focused roadmap and active cross-chain ecosystem expansion, with community sentiment split between those accumulating on price weakness and others expressing frustration over long-term volatility. Enthusiasts are highlighting NEAR Intents and deflationary tokenomics as key fundamental catalysts that differentiate the project from broader market laggards.

ElizaOS

ELIZAOS is experiencing intense community polarization, with a vocal segment alleging systematic market manipulation by insiders and creators, while others remain optimistic about its long-term potential as an AI-agent operating system. This conflict is fueling high trading volume and volatility, as participants debate the project's viability amidst ongoing allegations of fraudulent practices.

Rheinmetall AG is a holding company, which engages in the provision of development and sale of components, systems, and services for the security and civil industries. It operates through the following segments: Vehicle Systems, Weapon and Ammunition, Electronic Solutions, Sensors and Actuators, Materials and Trade, and Others. The Vehicle Systems segment offers a diverse portfolio of vehicles, including combat, support, logistics, and special vehicles. The Weapon and Ammunition segment includes products and solutions for threat-appropriate, firepower as well as comprehensive protection. The Electronic Solutions segment is involved in the chain of effects in the system network, from sensors and the networking of platforms and soldiers to the automated connection of effectors, as well as solutions for protection in cyberspace. The Sensors and Actuators consists of a product portfolio with exhaust gas recirculation systems, throttle valves, control dampers, and exhaust flaps for electromotors, solenoid valves, actuators and valve train systems, oil, water, and vacuum pumps for passenger cars, commercial vehicles, and light and heavy-duty off-road applications, as well as industrial solutions. The Materials and Trade segment focuses on the development of system components for the basic motor. The company was founded by Heinrich Ehrhardt on April 13, 1889 and is headquartered in Duesseldorf, Germany.

Rheinmetall AG - ADR

Rheinmetall AG is currently trending as investors capitalize on massive growth catalysts within the European defense sector, including major contract wins for artillery, armored vehicles, and naval systems. The community is actively debating the stock's long-term potential fueled by expanded NATO spending targets, while simultaneously monitoring volatility driven by shifts in geopolitical strategy and institutional accumulation.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is seeing heightened community engagement as investors speculate on its role as a high-performance, EVM-compatible Layer 1 blockchain, with many discussing its potential to scale and compete with established chains. Supporters are actively focused on long-term accumulation and staking strategies, often debating how market volatility and token unlock schedules influence its price discovery phase.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom Video Communications is attracting attention as it tests long-term technical resistance, with traders debating whether a breakout from its multi-year base is fueled by its strategic early-stage investment in Anthropic or legitimate software business improvements. While some investors view the stock as an undervalued AI proxy with a strong balance sheet, others remain skeptical, pointing to intense competition from Microsoft Teams and historical volatility as reasons for caution.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is facing intense scrutiny as a blend of soft sales commentary and a viral CEO interview creates a challenging narrative for the stock, causing investors to weigh the company's real estate-backed stability against its slowing consumer demand. While some community members view the current pullback as a value-buying opportunity in a defensive compounder, others are actively betting on further downside, citing leadership concerns and a broader retail consumer slowdown.

ETF Series Solutions - ESS U.S.Global Jets ETF

US Global Jets ETF

The US Global Jets ETF (JETS) is trending as investors weigh strong record-breaking travel demand against headwinds from geopolitical instability in the Middle East and concerns over elevated fuel and labor costs. Community discussions are centered on whether the sector will see a rally driven by easing oil prices or if ongoing operational disruptions and macroeconomic uncertainty will suppress potential growth.

Booking Holdings, Inc. engages in the provision of online travel and related solutions. The firm offers services through the following brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. It provides accommodation reservations including hotels, hostels, apartments, vacation rentals, and other properties. The company was founded by Jay Scott Walker on July 18, 1997, and is headquartered in Norwalk, CT.

Booking Holdings Inc

Booking Holdings is trending as investors react to a strong quarterly earnings report that beat revenue and profit expectations, signaling resilient global travel demand. Market participants are actively discussing the company's performance, current outlook, and its positioning within the competitive online travel sector.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing intense community speculation and active buying volume, fueled by rumors of major exchange relistings, upcoming network upgrades, and hopes for significant token burns. Investors are closely monitoring price action for a potential breakout, with many in the community expressing long-term optimism about a project revival despite ongoing concerns regarding past volatility and supply dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>First-quarter revenue growth was driven by a 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, a serious kidney disease.</li><li>The biotech firm reiterated its FY2026 revenue guidance of $315 million to $325 million.</li><li>Aurinia’s earnings of $0.25 per share topped analysts’ estimates of $0.20 per share.</li></ul>Shares of Aurinia Pharmaceuticals (AUPH) fell more than 10% on Thursday, marking their steepest single-day drop in over nine months, as investors appeared unsettled by the lack of an earnings call and limited pipeline updates despite the company posting a first-quarter earnings beat.The report marked Aurinia’s first quarterly update since a <a href="https://stocktwits.com/news-articles/markets/equity/auph-stock-jumps-ceo-shake-up-aurinia-tang-greenleaf/cZ3mLhSRI0p">sweeping leadership overhaul</a> in March. The company appointed industry veteran Kevin Tang as CEO to replace Peter Greenleaf, who served in the position for seven years. The company also named Michael Hearne as CFO, Ryan Cole as COO, and Thomas Wei as Chief Scientific Officer.<h2 class="st-heading-2">AUPH Sees Revenue Growth Across All Segments</h2>Aurinia reported first-quarter revenue of $77.7 million, up 24% year over year and ahead of Wall Street expectations of about $77 million, according to Fiscal.ai data. The company posted earnings of $0.25 per share, topping analysts’ estimates of $0.20 per share.Revenue growth was driven by a 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, a serious kidney disease. Meanwhile, revenue from Aurinia’s licensing, collaboration, and royalty agreement with Otsuka rose 64% to $4.1 million.The biotech firm reiterated its full-year 2026 revenue guidance of $315 million to $325 million, up 11% to 15% year over year.&nbsp;&nbsp;<h2 class="st-heading-2">Retail Questions Lack Of Information</h2>Despite the sharp intraday fall, retail sentiment for <a href="https://stocktwits.com/symbol/AUPH">AUPH</a> turned ‘bullish’ from ‘bearish’ a day earlier, while message volumes were ‘high.’One user questioned the lack of an earnings call and asked why the company did not provide updates on its clinical trials for Aritinercept, an autoimmune disease drug candidate under development for three potential uses. The company had earlier announced plans to begin a clinical study of Aritinercept in the first half of 2026.<stembedurl>https://stocktwits.com/Whpbauer/message/652570535</stembedurl>Another user remained bullish but said they hoped for more clinical updates and merger information.<stembedurl>https://stocktwits.com/Prosperity1_/message/652565629</stembedurl>The stock has shed around 10% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/kala-stock-record-low-reverse-split/cZXbKgSReQX">KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aurinia Pharmaceuticals logo is seen displayed on a smartphone screen

AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors

Aurinia reported Q1 revenue of $77.7 million, ahead of Wall Street expectations of about $77 million, according to Fiscal.ai data.

Equity

Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +38.89% and +0.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals Inc. Profit Advances In Q1

(RTTNews) - Aurinia Pharmaceuticals Inc. (AUP.V) revealed earnings for its first quarter that Increased, from last year...

Guardian Pharmacy Services (GRDN) Q1 Earnings and Revenues Surpass Estimates

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +20.83% and +2.10%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on Monday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at...

Short Interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Decreases By 15.7%

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 9,112,230 shares, a decrease of 15.7% from the March 31st total of 10,809,496 shares...

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) (TSE:AUP) have been assigned a consensus rating of "Hold" from the six ratings firms that are covering the company, MarketBeat...

Select Medical (SEM) Lags Q1 Earnings Estimates

Select Medical (SEM) delivered earnings and revenue surprises of -15.91% and +1.54%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (NASDAQ:AUPH) Hits New 1-Year High  - Still a Buy?

Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 1-Year High - Time to Buy...

Tudor Investment Corp ET AL Buys Shares of 65,964 Aurinia Pharmaceuticals Inc $AUPH

Tudor Investment Corp ET AL bought a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) (TSE:AUP) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 65,964 shares of the biotechnology company's stock, valued...

$AUPH Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.26 up 52.94% YoY
• Reported revenue of $77.7M up 24.40% YoY
• Aurinia Pharmaceuticals Inc. expects its R&amp;D expense to increase as the company progresses development activities and anticipates SG&amp;A expense in 2026 to remain substantially consistent with 2025, funding operations with existing cash or cash flows.

Stocktwits

Aurinia Pharmaceuticals Inc

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.26 up 52.94% YoY
• Reported revenue of $77.7M up 24.40% YoY
• Aurinia Pharmaceuticals Inc. expects its R&D expense to increase as the company progresses development activities and anticipates SG&A expense in 2026 to remain substantially consistent with 2025, funding operations with existing cash or cash flows.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Earnings Recap

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc